Cantor Fitzgerald Reaffirms Overweight Rating for Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics (NASDAQ:KROS - Get Free Report)'s stock had its "overweight" rating restated by stock analysts at Cantor Fitzgerald in a research note issued to investors on Friday,Benzinga reports.

A number of other equities research analysts have also recently commented on KROS. Bank of America reduced their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a report on Thursday, September 12th. Jefferies Financial Group began coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating for the company. Guggenheim initiated coverage on Keros Therapeutics in a report on Monday, September 23rd. They issued a "buy" rating and a $96.00 price target on the stock. Wedbush restated an "outperform" rating and set a $84.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, Keros Therapeutics presently has an average rating of "Buy" and an average price target of $88.89.

Keros Therapeutics Trading Up 0.8 %

Shares of Keros Therapeutics stock opened at $54.28 on Friday. The business has a 50-day moving average price of $59.33 and a two-hundred day moving average price of $52.29. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The company has a market cap of $2.20 billion, a P/E ratio of -10.35 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business's quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.33) EPS. Equities research analysts forecast that Keros Therapeutics will post -5.28 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. FMR LLC raised its holdings in Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company's stock valued at $284,493,000 after acquiring an additional 179,374 shares during the period. Alkeon Capital Management LLC raised its stake in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock valued at $110,194,000 after purchasing an additional 298,694 shares during the period. Vanguard Group Inc. lifted its holdings in Keros Therapeutics by 7.9% during the 1st quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company's stock worth $102,329,000 after purchasing an additional 113,563 shares in the last quarter. Darwin Global Management Ltd. boosted its stake in Keros Therapeutics by 6.3% in the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company's stock worth $68,772,000 after purchasing an additional 89,952 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company's stock worth $80,666,000 after purchasing an additional 176,803 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.